Literature DB >> 17897756

Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Mingtao Zeng1, Qingfu Xu, Md Elias, Michael E Pichichero, Lance L Simpson, Leonard A Smith.   

Abstract

Botulinum neurotoxins cause botulism, a neuroparalytic disease in humans and animals. We constructed a replication-incompetent adenovirus encoding a synthesized codon-optimized gene for expression of the heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C). This recombinant human serotype 5 adenoviral vector (Ad5) was evaluated as a genetic vaccine candidate against botulism caused by BoNT/C in a mouse model. A one-time intramuscular injection with 10(5) to 2 x 10(7)pfu of adenoviral vectors elicited robust serum antibody responses against H(C)50 of BoNT/C as assessed by ELISA. Immune sera showed high potency in neutralizing the active BoNT/C in vitro. After a single dose of 2 x 10(7)pfu adenoviral vectors, the animals were completely protected against intraperitoneal challenge with 100 x MLD(50) of active BoNT/C. The protective immunity appeared to be vaccine dose-dependent. The anti-toxin protective immunity could last for at least 7 months without a booster injection. In addition, we observed that pre-existing immunity to the wild-type Ad5 in the host had no significant influence on the protective efficacy of vaccination. The data suggest that an adenovirus-vectored genetic vaccine is a highly efficient prophylaxis candidate against botulism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897756      PMCID: PMC2077857          DOI: 10.1016/j.vaccine.2007.08.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

Review 1.  Technical issues in construction of nucleic acid vaccines.

Authors:  Peter F Ertl; Lindy L Thomsen
Journal:  Methods       Date:  2003-11       Impact factor: 3.608

2.  Studies on immunity to toxins of Clostridium botulinum. V. Detoxification of purified type A and type B toxins, and the antigenicity of univalent and bivalent aluminium phosphate adsorbed toxoids.

Authors:  G G WRIGHT; J T DUFF; M A FIOCK; H B DEVLIN; R L SODERSTROM
Journal:  J Immunol       Date:  1960-04       Impact factor: 5.422

3.  Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

Authors:  Robert P Webb; Theresa J Smith; Patrick M Wright; Vicki A Montgomery; Michael M Meagher; Leonard A Smith
Journal:  Vaccine       Date:  2007-03-16       Impact factor: 3.641

4.  Infection of mouse liver by human adenovirus type 5.

Authors:  S J Duncan; F C Gordon; D W Gregory; J L McPhie; R Postlethwaite; R White; H N Willcox
Journal:  J Gen Virol       Date:  1978-07       Impact factor: 3.891

5.  Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

Authors:  Michael R Baldwin; William H Tepp; Christina L Pier; Marite Bradshaw; Mengfei Ho; Brenda A Wilson; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.

Authors:  M Z Atassi; B Z Dolimbek; M Hayakari; J L Middlebrook; B Whitney; M Oshima
Journal:  J Protein Chem       Date:  1996-10

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 8.  Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.

Authors:  M Z Atassi; M Oshima
Journal:  Crit Rev Immunol       Date:  1999       Impact factor: 2.214

9.  Adenovirus-based prime-boost immunization for rapid vaccination against anthrax.

Authors:  Michael J McConnell; Philip C Hanna; Michael J Imperiale
Journal:  Mol Ther       Date:  2007-01       Impact factor: 11.454

10.  Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

Authors:  M P Byrne; T J Smith; V A Montgomery; L A Smith
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more
  19 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

Review 2.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Junwei Li; Diana Diaz-Arévalo; Amit Kumar; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

4.  Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis.

Authors:  Ravinder Kaur; Shan Chen; Maria T Arévalo; Qingfu Xu; Yanping Chen; Mingtao Zeng
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

5.  Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.

Authors:  Sung-Youl Ko; Cheng Cheng; Wing-Pui Kong; Lingshu Wang; Masaru Kanekiyo; David Einfeld; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

6.  Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.

Authors:  Bikash Sahay; Natacha Colliou; Mojgan Zadeh; Yong Ge; Minghao Gong; Jennifer L Owen; Melissa Valletti; Christian Jobin; Mansour Mohamadzadeh
Journal:  Vaccine       Date:  2017-11-24       Impact factor: 3.641

7.  Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.

Authors:  Sangmu Jun; Beata Clapp; Dagmara Zlotkowska; Teri Hoyt; Kathryn Holderness; Massimo Maddaloni; David W Pascual
Journal:  Int Immunol       Date:  2011-12-29       Impact factor: 4.823

Review 8.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E.

Authors:  Aurore Burgain; Alice Rochard; Capucine Trollet; Christelle Mazuet; Michel R Popoff; Virginie Escriou; Daniel Scherman; Pascal Bigey
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.